Gerresheimer AG
XETRA:GXI

Watchlist Manager
Gerresheimer AG Logo
Gerresheimer AG
XETRA:GXI
Watchlist
Price: 24.18 EUR
Market Cap: €835.2m

EV/S

1.1
Current
37%
Cheaper
vs 3-y average of 1.7

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1.1
=
Enterprise Value
€2.2B
/
Revenue
€2.3B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1.1
=
Enterprise Value
€2.2B
/
Revenue
€2.3B

Valuation Scenarios

Gerresheimer AG is trading below its 3-year average

If EV/S returns to its 3-Year Average (1.7), the stock would be worth €38.68 (60% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+71%
Average Upside
54%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 1.1 €24.18
0%
3-Year Average 1.7 €38.68
+60%
5-Year Average 1.8 €41.24
+71%
Industry Average 1.7 €38.45
+59%
Country Average 1.3 €30.78
+27%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
€2.2B
/
Sep 2025
€2.3B
=
1.1
Current
€2.2B
/
Dec 2025
€2.3B
=
0.9
Forward
€2.2B
/
Dec 2026
€2.4B
=
0.9
Forward
€2.2B
/
Dec 2027
€2.5B
=
0.9
Forward
€2.2B
/
Nov 2028
€2.8B
=
0.8
Forward
€2.2B
/
Nov 2029
€2.9B
=
0.8
Forward
€2.2B
/
Nov 2030
€3B
=
0.7
Forward
€2.2B
/
Nov 2031
€3.5B
=
0.6
Forward
€2.2B
/
Nov 2032
€3.6B
=
0.6
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
DE
Gerresheimer AG
XETRA:GXI
835.2m EUR 1.1 35.8
US
PerkinElmer Inc
LSE:0KHE
936.1B USD 328.4 3 881
US
Thermo Fisher Scientific Inc
NYSE:TMO
173.3B USD 4.7 25.7
US
Danaher Corp
NYSE:DHR
126.5B USD 5.6 34.4
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 17.9 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
331.7B CNY 6.3 16.8
CH
Lonza Group AG
SIX:LONN
32.5B CHF 5.5 -119.8
US
Agilent Technologies Inc
NYSE:A
31.5B USD 4.8 25
US
Waters Corp
NYSE:WAT
28.7B USD 9.6 46.7
US
IQVIA Holdings Inc
NYSE:IQV
26.6B USD 2.4 19.8
US
Mettler-Toledo International Inc
NYSE:MTD
25.2B USD 6.9 29.7

Market Distribution

In line with most companies in Germany
Percentile
42nd
Based on 2 724 companies
42nd percentile
1.1
Low
0 — 0.7
Typical Range
0.7 — 2.5
High
2.5 —
Distribution Statistics
Germany
Min 0
30th Percentile 0.7
Median 1.3
70th Percentile 2.5
Max 21 171.2

Gerresheimer AG
Glance View

Gerresheimer AG, nestled in the heart of Germany, has evolved into a cornerstone of the pharmaceutical and healthcare industries. Its beginnings were humble, rooted in glass manufacturing over a century ago, but the company has since metamorphosed into a leading provider of specialized products for the global healthcare market. Today, Gerresheimer's portfolio stretches well beyond glass, encompassing a range of highly technical and innovative products. The company specializes in producing glass and plastic containers, including vials, ampoules, and cartridges, which are crucial for delivering drugs and vaccines safely to patients worldwide. Its sophisticated offerings extend to complex drug delivery devices like insulin pens and inhalers, showcasing its deep integration into the supply chains of major pharmaceutical companies. Gerresheimer's business model thrives on close partnerships with these pharmaceutical giants, crafting tailor-made solutions for diverse therapeutic areas. This strategic alignment positions it well amid growing global health needs and an aging population, driving steady demand for its high-margin products. Its operations are bolstered by an international footprint of production facilities, allowing for high-quality, efficient manufacturing and distribution. This network not only enhances its logistics but also supports the company's commitment to innovation, enabling it to meet specific regulatory and market requirements across different regions. Ultimately, Gerresheimer AG makes its mark and profits through a combination of cutting-edge technology, stringent quality standards, and strategic relationships, securing its place as a vital player in the global healthcare ecosystem.

GXI Intrinsic Value
88 EUR
Undervaluation 73%
Intrinsic Value
Price €24.18
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett